Unknown PHASE4 INTERVENTIONAL 2-arm NCT01360710

The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial

Sponsor: Baker Heart and Diabetes Institute

Conditions Abdominal Obesity Hypertension

Interventions Irbesartan Moxonidine

Updated 6 times since 2017 Last updated: Feb 1, 2012 Started: Jan 31, 2012 Primary completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Abdominal Obesity and Hypertension and is currently ongoing. Baker Heart and Diabetes Institute leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Nov 2020 — Jan 2021 [monthly]

Unknown Status PHASE4
Jun 2018 — Nov 2020 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baker Heart and Diabetes Institute

Data source: Baker Heart and Diabetes Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Prahran, Australia